Q-omics provides the consensus-scored TM2D3 profile across patient tissues and cancer cell-line models. TM2D3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TM2D3 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TM2D3 RNA expression shows 20,114 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, HNSC, and UVM as cancer lineages where TM2D3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM2D3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM2D3 survival associations across molecular data types. TM2D3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM2D3 RNA expression–survival associations across cancer types. High TM2D3 expression shows unfavorable associations in UVM, LIHC and CESC, but favorable associations in UCEC, SKCM and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for TM2D3 RNA expression.
This table summarizes TM2D3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TM2D3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM2D3 shows lower tumor expression in LUAD and higher tumor expression in HNSC, KIRC, LIHC, COAD and CHOL. The HNSC box plot shows higher TM2D3 RNA expression in tumor versus normal tissue (log2 FC = +0.835, t-test p < 0.001).
This table shows molecular features associated with TM2D3 in patient tissues and cancer cell lines. In patient samples, TM2D3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TM2D3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
